Aquatic Capital Management LLC bought a new position in Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY - Free Report) in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund bought 11,127 shares of the company's stock, valued at approximately $383,000.
Other hedge funds have also modified their holdings of the company. Vanguard Group Inc. lifted its position in Harmony Biosciences by 36.4% during the fourth quarter. Vanguard Group Inc. now owns 4,733,609 shares of the company's stock valued at $162,883,000 after acquiring an additional 1,262,362 shares during the last quarter. Marshall Wace LLP boosted its position in shares of Harmony Biosciences by 165.2% in the 4th quarter. Marshall Wace LLP now owns 929,744 shares of the company's stock worth $31,992,000 after purchasing an additional 579,103 shares in the last quarter. Norges Bank purchased a new position in Harmony Biosciences during the 4th quarter worth $16,118,000. Pacer Advisors Inc. increased its position in Harmony Biosciences by 18.2% during the 4th quarter. Pacer Advisors Inc. now owns 2,279,918 shares of the company's stock valued at $78,452,000 after buying an additional 351,582 shares in the last quarter. Finally, Invesco Ltd. increased its position in Harmony Biosciences by 173.9% during the 4th quarter. Invesco Ltd. now owns 449,180 shares of the company's stock valued at $15,456,000 after buying an additional 285,156 shares in the last quarter. 86.23% of the stock is owned by hedge funds and other institutional investors.
Analyst Ratings Changes
A number of brokerages have recently weighed in on HRMY. Mizuho boosted their price target on Harmony Biosciences from $42.00 to $44.00 and gave the stock an "outperform" rating in a research note on Tuesday, March 18th. UBS Group cut their price target on shares of Harmony Biosciences from $55.00 to $48.00 and set a "buy" rating on the stock in a research note on Monday, April 28th. Deutsche Bank Aktiengesellschaft began coverage on shares of Harmony Biosciences in a research note on Tuesday, February 11th. They set a "buy" rating and a $55.00 price objective for the company. Needham & Company LLC reissued a "buy" rating and issued a $50.00 target price on shares of Harmony Biosciences in a research report on Tuesday, April 8th. Finally, HC Wainwright reaffirmed a "buy" rating and set a $70.00 price target on shares of Harmony Biosciences in a research report on Tuesday, April 8th. Nine equities research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, Harmony Biosciences has a consensus rating of "Buy" and a consensus target price of $52.44.
View Our Latest Research Report on Harmony Biosciences
Harmony Biosciences Stock Performance
NASDAQ HRMY opened at $30.32 on Friday. The firm has a market capitalization of $1.74 billion, a P/E ratio of 14.37, a PEG ratio of 0.47 and a beta of 0.80. The stock has a 50-day simple moving average of $31.41 and a two-hundred day simple moving average of $34.09. The company has a debt-to-equity ratio of 0.28, a quick ratio of 3.20 and a current ratio of 3.24. Harmony Biosciences Holdings, Inc. has a fifty-two week low of $26.47 and a fifty-two week high of $41.61.
Harmony Biosciences (NASDAQ:HRMY - Get Free Report) last announced its quarterly earnings results on Tuesday, February 25th. The company reported $0.85 earnings per share for the quarter, beating the consensus estimate of $0.74 by $0.11. Harmony Biosciences had a return on equity of 23.16% and a net margin of 17.98%. The company had revenue of $201.30 million during the quarter, compared to analysts' expectations of $201.25 million. During the same period last year, the business earned $0.45 earnings per share. Harmony Biosciences's quarterly revenue was up 19.5% on a year-over-year basis. On average, equities analysts forecast that Harmony Biosciences Holdings, Inc. will post 2.43 earnings per share for the current year.
About Harmony Biosciences
(
Free Report)
Harmony Biosciences Holdings, Inc, a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare and other neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy.
Further Reading
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Harmony Biosciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Harmony Biosciences wasn't on the list.
While Harmony Biosciences currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
